Research & News
Evidence-based explainers on retatrutide and GLP-1 science, and a weekly roundup of peptide news with a US focus. Every article cites primary sources such as peer-reviewed journals, ClinicalTrials.gov, the FDA and company disclosures.
Latest peptide news
New article every weekFDA Sends Interim Peptide Compounding Policy to White House Review
FDA has sent an interim peptide compounding policy to White House review. What it may cover, what it excludes, and why retatrutide isn't part of it.
News · October 19, 2026FDA Received Reports of Two Deaths Tied to Bootleg Retatrutide
Two unverified FDA adverse event reports describe deaths after use of black-market retatrutide, as poison center exposure reports keep climbing in 2026.
Research explainers
GLP-1 vs Dual vs Triple Agonists: What the Research Shows
Semaglutide, tirzepatide and retatrutide compared: how single, dual and triple incretin agonists work, what trials found, and what is still unknown.
Research · October 12, 2026Retatrutide Clinical Trial Results Explained (2023–2026)
Every major retatrutide trial in one place: phase 2 NEJM data, TRIUMPH-1 to TRIUMPH-4, TRANSCEND-T2D-1, side effects and the FDA timeline.